Wednesday, August 12, 2020

Man Industries (India) Limited reports Financial Results

  • Q1FY21 Total revenue of Rs. 4,101 million as against 2,447 million up by 68% YoY
  • Q1FY21 EBITDA for the period stands at Rs. 555 million as against 282 million up by 97% YoY
  • Q1FY21 PAT for the period stands at Rs. 174 Million as against 27 Million up by 549% YoY


Mumbai, August 12, 2020: MAN Industries (India) Limited, one of the leading Large Diameter Pipe manufacturing company has announced today its unaudited financial results for the Quarter ended June 30, 2020. The company reported total revenue of ₹ 4,104 Million in Q1FY21. EBITDA Margin stands at 13.5% as compared to 11.5% YoY up by 200 bps and PAT Margin Stands at 4.2% as compared to 1.1% YoY up by 314 bps.

Commenting upon the performance and future outlook of the Company, Dr. R.C. Mansukhani, Chairman said “All our plant operations have resumed successfully and we are back on track in terms of order execution. We are seeing good traction from domestic as well as international market on the back of revival of demand from key geographies and domestic sector already doing well with ample opportunities from several upcoming oil and gas and water projects like Nal se Jal and river linking. We expect good order Inflows from both domestic as well as international market in the near term”.

The unexecuted order book as on date is approximately Rs. 14,000 Million to be executed in the current financial year.

The company continues to have a robust book of outstanding bids for more than Rs. 1,80,000 Million at various stages of evaluation for several Oil, Gas and Water projects in India and abroad. The company therefore expects good order inflow in near future. 


Indian Terrain gears up for the new normal


  • ~ Completes 20 successful years as a strong national brand ~
  • ~Further expands retail footprint in the country with store launches in Tier2 & Tier3 markets~
  • Mumbai : As the world gearing up to win against COVID-19 and its unprecedented impact on humanity and economies, people and businesses are learning to embrace the new normal and look at adapting ways and means to bounce back from the current situation. With a vision to succeed in a new business landscape and a deeper commitment to offer best-in-class quality product to customers, echoing the nation’s clarion call of creating strong national brands, Indian Terrain with its authentically Indian roots originating in Madras,  is further expanding its retail footprint in the country with the launch of 15 new retail stores in Tier2 and Tier3 markets including Hubli, Lucknow, Siwan, Ganganagar, Ooty and more in FY 20-21.
  • The leading menswear & boyswear brand, Indian Terrain has also successfully completed 20 years of its operations in India.
  • Speaking on the occasion, Mr. Charath Narsimhan, Managing Director, Indian Terrain Fashions Limited said, “While the pandemic continues to present unprecedented challenges, it is integral to adopt to the new normal and map a strategic journey that can benefit the community as a whole. To mitigate the impact of the current situation, we need to evolve and adopt newer ways of reaching out to the consumers. Indian Terrain’s passion and resilience is enhanced by Spirit of Man and the exuberance of India. Staying true to the qualities of the brand, we are currently expanding our stores in Tier II and Tier III cities across the county and further expanding our business portfolio.”
  • He further added“With the impetus on digital in the current situation, digital engagement has been a clear and predictable trend. Riding the wave and adapting to our consumers’ buying behaviours we have invested in our digital strategy to strengthen our e-commerce set-up and focussed on building strong strategic partnerships with marketplaces such as Myntra & Flipkart and soon with Nykaa to ensure higher visibility. The brand has also re-launched its own website enabling an enhanced user interface and omni channel experience with order fulfilment being implemented from stores.”
  • Indian Terrain has introduced multiple consumer centric initiatives for seamless engagement. The brand has launched a “Store to Door” service whereby a curated virtual catalogue is sent to the customer via WhatsApp & product is delivered at the customer’s doorstep. Indian Terrain is further strengthening its delivery models for customers.
  • Further, keeping in mind the importance of safety & hygiene in the current situation, all Indian Terrain stores have undertaken precautionary measures to ensure customers have a safe & delightful shopping experience. Prior appointments and digital payments are encouraged. Sanitizers and masks are placed on every floor. Customers are encouraged to wear masks and follow social distancing norms. The stores including the trial rooms are regularly sanitized.
  • The brand will further launch its new collection in the month of August 2020.
  • ***
  • Indian Terrain Fashions Ltd. [BSE: 533329 | NSE: INDTERRAIN] is one of India’s leading men’s & boys wear brand offering a complete range of casual wear and sportswear. Having opened its first store in September 2000, the company was listed in 2011, following a demerger from its parent company. The range of men’s apparel includes shirts, trousers, t-shirts, shorts, sweaters, jackets, and denims. In September 2015, company introduced a brand called “Indian Terrain BOY”. The collection has been designed for boys between the ages of 4 and 16 years the categories offered include shirts, t-Shirts, trousers, shorts, winter-wear and denims. With a turnover of over ₹900 Crore, the company today retails across the country through 1000+ Multi Brand Outlets, 400+ doors of Large Format Stores, 160+ Exclusive Brand Outlets, and is available through key e-commerce platforms as well.
  • Website link:

Experience Luxurious Hygiene like None VitrA V-Care Smart Toilet

VitrA, the leading bathroom solutions brand of Eczacıbaşı Building Products Division in Turkey introduces its technologically advanced V-Care Smart Toilet. Designed by multi-award-winning German design studio NOA in collaboration with the VitrA Design team, V-Care Smart Toilet provides an innovative, user-friendly, fully customizable personal hygiene washing experience.

V-Care Smart Toilet, the new generation of shower toilets from VitrA, redefines the standard by combining the functionality of a toilet and the cleaning properties of a bidet into a stylish WC that can seamlessly integrate into your bathroom. Washing with water after using the toilet is becoming increasingly popular as people understand the health benefits. It offers all the features of a modern WC along with added advantages of a touch-free toilet, elegant look and a technologically advanced bathroom.

This remote-control VitrA innovation offers the ultimate in sanitation and comfort with its self-cleaning bidet nozzle, auto open-close, adjustable water temperature, different washing options, air-drying and odor absorption features. It offers drying temperature adjustment as well as water pressure adjustment so that you can use the WC with maximum comfort.  The seating area is very ergonomically designed as well.

The V-Care Smart Toilet is easily controlled by the intuitively engineered remote control or the side control panel; providing easy access to the simple cleaning and drying functions.  The remote control is very easy to use and helps in controlling features like nozzle position, water pressure and the temperature of the water and the seat.

V-care Smart Toilet has different washing alternatives, the integrated bidet nozzle provides gender-specific washing options, and the bidet nozzle cleans itself before and after each use. It also allows the user to regulate the water as desired. Offering elegant designs with advanced technology, it virtually suits any kind of bathroom.

VitrA Rim-ex keeps the toilet 95% more hygienic according to a standard WC. Due to the rimless design of the inner bowl and hidden installation technology it also makes the WC easy to clean and keep germ-free thanks to its rimless design. V-Care Smart Toilet fights against the limescale deposits with a special decalcification solution, providing protection from the damaging effects of limescale deposits.

With this new introduction,  V-Care Smart Toilet not only offers improved hygiene but also increased comfort, innovative design, durability and adds an aesthetic appeal to your bathroom. 

Tuesday, August 11, 2020

PNB honours the families of Martyrs' of Galwan Valley


Mumbai : As India gears up to celebrate its 74th Independence Day, nation’s second-largest banking institution, Punjab National Bank salutes and honours the family members of the soldiers who were martyred in Galwan Valley, on the intervening night of June 15th and 16th. Punjab National Bank felicitated the families of the soldiers by giving a memento and shawl on behalf of the bank.

Across India, Punjab National Bank senior officials personally visited and comforted the families of these courageous martyrs who made their supreme sacrifice in the service of our nation. PNB will always remember their sacrifice. The bank also assured the families that they will always support them and provide all possible assistance required.

The family members of the martyrs were experiencing a mixed set of emotions. On the one hand, feeling the sorrowful loss of their loved ones and on the other, the pride at being honoured and rewarded.

Families of the martyrs thanked the bank management for the generosity and contribution by PNB.

PNB Parivar honouring families of the martyrs across the nation:

  • Martyr Col.B Santosh Babu, who was the commanding officer of the 16th Bihar Regiment. PNB officials visited their residence in Hyderabad and felicitated Smt. Santoshi, wife of Col. Santosh Babu with a shawl and memento
  • PNB Pathankot branch Zonal manager Sh Onkarjit Singh, Circle Head Sh Parminder Singh Jaswal, Chief Manager Sh. Lalit Mehra, and other officials visited Martyr Satnam Singh, Amritsar residence and felicitated wife Smt. Jaswinder Kaur, father Sh Jaagir Singh and mother Smt Kashmir Kaur and other family members. (Photo Attached)
  • PNB Madurai branch officials visited the residence of Martyr Mr. K. Palani in Ramnad and honoured his family members with a shawl and memento
  • PNB Bistupur, CO Ranchi (South) Circle Head Sh Deepak Shrivastava, and other officials visited the residence of Martyr Sh. Ganesh Hansda and felicitated his family members with a shawl and memento. (Photo Attached)
  • PNB Bhilai Circle Head Sh. Jitendra Swain visited the residence of Martyr Ganesh Ram Kunjan and honoured his family members with a shawl and memento. (Photo Attached)
  • PNB Bokaro branch’s Zonal Manager and Chief Manager Sh Rajesh Arora and other officials visited the residence of Martyr Sh. Kundan Kumar Ojha in Sahibganj and felicitated his family members with a shawl and memento. (Photo Attached)
  • PNB Rewa branch, Bhopal officials visited Martyr Nayak Deepak Kumar’s residence and met his family members for offering prayers, a shawl and memento. (Photo Attached)
  • PNB Patna branch officials visited Martyr Sunil Kumar Singh’s residence and felicitated his family member with a shawl and memento. (Photo Attached)
  • PNB Bihita, Patna branch officials visited Martyr Jaykishore Singh’s residence and felicitated his family members with a shawl and memento. (Photo Attached)
  • PNB Patna branch officials visited Martyr Kundan Kumar’s residence in Saharsa Bhagalpur and felicitated his family members with a shawl and memento
  • PNB Arrah, Bhojpur branch officials visited Martyr Chandan Kumar Yadav’s residence in Jagdishpur and felicitated his family members with a shawl and memento
  • PNB Darbhanga branch officials visited Martyr Aman Kumar Yadav’s residence in Sultanpur and felicitated his family members with a shawl and memento
  • PNB Muzaffarpur branch officials visited Martyr Jaykishore Singh’s residence in Jandaha and felicitated his family members with a shawl and memento

IIM Sambalpur conducts its first ever virtual induction program, reiterates its commitment towards gender diversity


11th August 2020, Sambalpur: Succeeding a pioneering online admission process, IIM Sambalpur, one of the most promising and dynamic management institutions among the new generation IIMs of the country welcomed their MBA Class 2020-22 and PhD Class 2020 through an august inauguration programme. The virtual session was graced by distinguished and esteemed guests which included Chief Guest Mr. Guru Prasad Mohapatra, IAS, Secretary, Department for Promotion of Industry and Internal Trade (DPIIT) and Guest of Honour and Keynote Speaker, Mr. Prabhjeet Singh, President, Uber India & South Asia. The inaugural programme also witnessed a welcome address by Prof Mahadeo Jaiswal, Director, IIM Sambalpur. The MBA Program was introduced by Prof. Atri Sengupta, Chairman, PGP and the PhD program of the institute was introduced by Prof. Balamurugan Annamalai, Chairman, PhD Program. The 6th MBA batch with its full strength of 168 students is a vibrant combination of gender and academic diversity.


Speaking on the occasion, Prof Mahadeo Jaiswal, Director, IIM Sambalpur, said, “Inclusivity is one of the core values of IIM Sambalpur and I am glad to say that we have the most diverse class profile this year, in terms of gender with 40% female candidates, socio-economic class and diverse academic background with rich industry experience, representing more than 17 states/UT’s of the country. We have increased our seats from a 100 to 165 this year. Among the students who have taken admission this year, 72% are from Engineering background while rest 28% from other subjects and 60% come with prior work experience in the industry. I am confident that we will be able to produce Responsible Leaders with an Entrepreneurial blend of mind from these Students.”


The 5-day Induction program will be addressed by a host of eminent and notable leaders from the industry and the Government. The guests who will honour the induction week include Mr. Dinesh Murugesan, Head HR, DSM, Mr. Rasmi Swain, Principal- Risk Management & Information Security at Infosys Member, SMU (Dallas), Shri V. Srinivas, IAS, Additional Secretary, Department of Administrative Reforms & Public Grievances, GOI and Director General, National Centre for Good Governance, Mr Prasad Unnikrishnan, Partner, KPMG, Prof. M R Dixit, IIM Ahmedabad, Mr Tarun Chugh, CEO, Bajaj Allianz, Dr. E Sankara Rao, CEO & MD IFCI Ltd, Prof Sabyasachi Sinha IIM Lucknow, Mr. Umesh Adhikary, President, Chairman's Office Aditya Birla Group, Mr. Siddhartha Gupta, CEO Mercer Mettl, Ms. Prativa Mohapatra, Vice President, Sales for IBM India/South Asia, Mr.Subrat Tripathy, Chief Executive Officer, The Dhamra Port Company Ltd., and Mr. Jyoti Kumar Agarwal, Director Finance, JSW.


Owing to the current circumstances, IIM Sambalpur will be conducting online classes with the help of several digital tools and processes to facilitate effective learning for its students. Taking forth the concept of Flipped classrooms, Learning Management Software like Moodle will be utilized, and students and faculty members will interact regularly through VCFurthermore, the institute has smart classrooms equipped with SMART Boards, where students can login and access notes, presentations, curriculum schedules and even test their own knowledge through built-in quizzes. All examinations of IIM Sambalpur will be conducted through online processes as well, either by using online proctoring systems for descriptive exams or using LMS for quiz and multiple-choice exams. Team projects will also be conducted virtually as per the trend in industry.


About Indian Institute of Management Sambalpur:

Indian Institute of Management Sambalpur (IIM-S) is one of the most promising and dynamic management institutions among the new generation IIMs of the country located in Sambalpur, Odisha, India. IIM Sambalpur was established by MHRD, GOI in 2015 and was declared as an Institute of National Importance as per the IIM 2017 Act. The Institute is already taking positive steps since its inception as a place for Entrepreneurial Innovation and Experiential Learning. Located amidst hills and rivers surrounded by large number of big manufacturing industry, IIM-S currently offers full time Master in Business Administration (MBA) and PhD programs and more courses to be added in near future. The Institute outscores all other IIM’s in terms of its gender diversity and its unique experiential learning pedagogy called “Flipped Classroom”. 

ELGi’s AB ‘Always Better’ Series powers the Indian pharmaceutical industry

¤  India’s leading pharmaceutical companies rely on an ELGi AB Series oil free screw air compressor for sensitive, critical processes.


¤  The AB series delivers certified Class ‘0’, 100% oil free compressed air with low cost of ownership.


CLASS ‘0’ CERTIFIED: A no compromise oil free air solution for sensitive industry applications.
LOWER LIFE-CYCLE COST: efficient rotors with best in class performance and optimal system configuration in single stage operation.
LOWER MAINTENANCE COST: Enhanced life and performance of the compressor due to fewer moving parts at low operating speeds.
HIGHER RELIABILITY and peace of mind.

Mumbai, August 11th, 2020: India’s leading pharmaceutical companies rely on the ELGi ((BSE: 522074 NSE: ELGIEQUIP)) AB series range of oil free screw compressors, to deliver pure, clean, class “0” oil free air. With high reliability, consistent air quality, better return on investment, lower cost of ownership, and fast, efficient service support for sensitive applications with moisture content between +3°C, to -20°C PDP; the AB series range of air compressors meets the ISO 8573–1 compliance requirements. In addition, the ELGi AB Series delivers unmatched air quality in line with the ISO8573-Class 7 compliance norms ensuring zero traces of microbial contaminants. With the IS:10500:2012 certification for water quality, the AB series also guarantees the safest pneumatic air for the pharmaceutical industry. The sheer performance of the ELGi AB Series, coupled with its compelling value proposition has resulted in India’s leading pharmaceutical companies replacing existing machines with the AB series, while successful installations, have prompted pharmaceutical companies, across the country, to revisit their entire fleet of air compressors.

India’s pharmaceutical industry is forecasted to grow at 22.4% annually, to US $100 billion by 2025;  addressing over 50% of the global demand for vaccines, 40%  of generic demand in the US and 25%  of all medicine requirements in the UK. Dr. Jairam Varadaraj, Managing Director, Elgi Equipments Ltd said “In light of the pandemic, India’s pharmaceutical industry has a tremendous opportunity to play a pivotal role in global healthcare. With growing FDA scrutiny, strict warnings over toxic impurities and delicate pharmaceutical manufacturing processes, the quality of compressed air meeting the highest standards, is of quintessential importance. On the other hand, continuous air supply must be guaranteed, since a disruption can lead to an immense loss of production. At ELGi, we endeavoured to address the needs of the pharmaceutical manufacturing industry in a new way. The ELGi AB ‘Always Better’ series is a disruption in oil free compressed air technology, and we’re delighted to witness its growing adoption as the customer’s choice for sensitive pharmaceutical applications.”

Pharmaceutical customers traditionally buy oil lubricated compressors for requirements below 500cfm (90kW) owing to low capital investments, and conventional oil free compressors, to meet stringent air quality requirements. The flip side of using lubricated screws is the multi-layer filtration systems which increase pressure drop and cause down time due to the replacement of oil filters resulting in increased lifecycle costs. On the other hand, conventional oil free compressors in this range, are normally air-cooled and also face reliability issues and temperature trips at high ambient temperature conditions (above 45°C), resulting in significant downtime and operational losses, in addition to excessive initial and running costs.

The ELGi AB Series is the #Always better choice; offering pharmaceutical manufacturing customers reliability and high performance at temperatures beyond 50°C due to the water injection inside the compression chamber. The AB Series delivers Class ‘0’ quality air, while the water in the closed circuit is insulated with proprietary material to ensure zero contamination due to corrosion.

The ELGi AB Series has a unique air cooling system which ensures ample condensation of water from air particles, aiding the self-replenishment of water in the closed loop. This eliminates the need for external water top-up and also reduces the load on the driers and the water management system. The in-built microbial inhibition system prevents microbial growth, across all scenarios of operation, thereby ensuring microbe free air. 

The ELGi AB Series operates with a single airend, as opposed to conventional oil free machines that operate with dual airends. This results in lower foot print, fewer rotating components and lower maintenance costs. Fitted with stainless steel rotors for better performance, every ELGi AB series air compressor comes with standard bearings for ease of maintenance. Additionally, the AB series range operates at a lower RPM, resulting in less wear and tear of rotating parts, low noise levels and reduced power consumption. Additionally, the low noise levels ensure the AB series does not require a dedicated compressor room and can be placed right next to the application area, thereby reducing costs involved with the build-up of additional infrastructure and compressed air supply systems.

Mr. Rajesh Premchandran, Director, ISAAME (India, South Asia, Africa and Middle East) said, The AB Series is a disruption in oil free compressed air technology, offering pharmaceutical customers a no-compromise, oil free solution at reduced lifecycle costs when compared with prevailing oil free technologies. With the AB Series compressors, pharmaceutical installations get the purest form of compressed air with higher efficiency, increased reliability and quicker return on investment.”

View our AB Series oil free compressors here.


Mumbai – Singapore Airlines (SIA) and the Temasek Foundation are partnering with the World Food Programme (WFP) to support the global Covid-19 response to help transport essential medical supplies and other health and humanitarian items by air to points of need around the world.

Providing the logistics backbone for global Covid-19 efforts, WFP operates a network of hubs and passenger and cargo airlinks to ensure a steady flow of supplies and support to the frontlines of the pandemic. Since these services commenced in May, WFP has managed more than 800 humanitarian flights to 159 countries, with enough cargo to fill 188 jumbo jets expected to require WFP transport in the coming weeks.

“While demand for WFP Common Services grows every week, resources are stretched incredibly thin and additional support is urgently needed,” said Amer Daoudi, WFP’s Covid-19 Corporate Response Director. “We are very grateful to Singapore Airlines and Temasek Foundation for stepping up so we can continue delivering life-saving supplies to those who need them most.”

Under this agreement, SIA is making ad-hoc charter flights and freight space in its scheduled services available on a cost-recovery basis, with flight costs being covered by a contribution of up to US$6.5 million from the Temasek Foundation.


Chin Yau Seng, Senior Vice President Cargo, Singapore Airlines, said: “It is a pleasure for SIA to partner with WFP and Temasek Foundation in this meaningful programme. This will allow us to draw on our expertise as a global airfreight provider and use our international network to deliver essential supplies to the points of need and help to make a positive impact on the communities that have been directly affected by Covid-19.”

Mr Ng Boon Heong, CEO of Temasek Foundation, said: “We are pleased to partner with the WFP and SIA to help make these flights possible. Together, we will be more capable in combating the Covid-19 global pandemic when we enable synergistic collaborations in the international community. This partnership is one way for us to ensure that essential supplies reach communities with the most need, even if they are separated by distance. We are pleased to enable two of the best in their respective fields to make this partnership possible.”

An estimated US$965 million is required to sustain WFP’s Common Services on behalf of the humanitarian and health community. To date only 21 percent of this sum has been received. WFP’s passenger and cargo flights are likely to grind to a halt at the end of August if no additional support is received.

During this challenging period, the SIA Group has stepped up to support the global fight against the Covid-19 pandemic.
 The SIA Group has facilitated multiple repatriation flights to bring back individuals stranded away from their home countries. SIA Cargo has also been transporting medical relief supplies and personal protective equipment to places where they are needed and playing its part in keeping supply lines for essential goods open at a critical time. The Group has also donated items such as blankets and helped to supply meals to communities that have been affected by the pandemic in Singapore.

About WFP

The United Nations World Food Programme is the world’s largest humanitarian organisation, saving lives in emergencies, building prosperity and supporting a sustainable future for people recovering from conflict, disasters and the impact of climate change.

Follow us on Twitter @wfp_media, @wfpsupplychain

About Singapore Airlines

The SIA Group’s history dates back to 1947 with the maiden flight of Malayan Airways Limited. The airline was later renamed Malaysian Airways Limited and then Malaysia-Singapore Airlines (MSA). In 1972, MSA split into Singapore Airlines (SIA) and Malaysian Airline System. Initially operating a modest fleet of 10 aircraft to 22 cities in 18 countries, SIA has since grown to be a world-class international airline group that is committed to the constant enhancement of the three main pillars of its brand promise: Service Excellence, Product Leadership and Network Connectivity.

About Temasek Foundation

Temasek Foundation supports programmes that uplift lives and communities in Singapore and beyond. We aim to strengthen social resilience, foster international exchange and enhance regional capabilities, and advance science and nature for a sustainable world.

For more information, visit


* * *

For more information please contact:

Singapore Airlines Public Affairs Department

Tel: (65) 6541-5880 (office hours)

Tel: (65) 9753-2126 (after office hours)



World Food Programme/Rome

Tyler Guthrie


Tel : +39 347 9672 412

Temasek Foundation/Singapore

Joshua Wong

Tel: (65) 8180-0741 

Mankind Pharma and Daewoong Pharmaceutical Announce Initiation of Phase 1 Clinical Trial on a ‘Novel’ Formulation of Niclosamide (DWRX2003) for COVID-19 Treatment

Mumbai, 11th August 2020: Daewoong Pharmaceutical Co., Ltd., South Korea (through its subsidiary, Daewoong Pharmaceutical India Pvt. Ltd.) and Mankind Pharma, fastest growing Indian Pharmaceutical Company, have collaborated for conducting Phase I clinical trial of a long acting intramuscular formulation of Niclosamide. The trial is designed towards addressing the need for a science-based investigation on this new formulation “Niclosamide (DWRX2003)” based on encouraging preclinical evidence for the treatment of COVID-19.

Niclosamide (DWRX2003) is already in clinical use as an anthelmintic; however, the current formulation is expected to be a longer acting variant for this alternate clinical indication. It is also expected to circumvent the downside of oral administration.

In vitro, Niclosamide (DWRX2003) was found to be 40, 26 & 15 times more potent than Remdesivir, Chloroquine & Ciclesonide respectively for its anti-viral action against SARS-CoV-2 virus. Also, the injectable intramuscular (IM) formulation of Niclosamide successfully removed the virus from lungs in animal tests, thereby countering viral infection, besides preventing cytokine storm which is the major cause of mortality in moderate to severe cases of COVID-19.

Through intensive motivated research, Daewoong researchers worked on quick development of the formulation to have reached the stage of “First-in-Human” evaluation, successful completion of which would immensely facilitate COVID-19 disease treatment.

Mr. Arjun Juneja, COO, Mankind Pharma Ltd. commented “We are continuously evaluating various target products for the treatment of Covid-19 in support to national response to COVID-19 pandemic.

In continuation to Mankind Pharma vision to service society by bringing quality and affordable medicine. We are excited to collaborate with Daewoong Pharmaceutical Co., Ltd. to bring Novel formulation of Niclosamide (DWRX2003) for the treatment of COVID-19 patients in India. We believe that the product would provide for a safe and effective alternative to patients suffering from this disease”.

We are already working on other unrelated COVID-19 focussed programs, in tandem with community and society as part of our Corporate Social Responsibility initiatives.

Sengho Jeon, CEO of Daewoong Pharmaceutical commented “Through development of candidates for COVID-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide innovative treatment option for patients suffering from COVID-19.

I believe Mankind Pharma is one of the best partner to accelerate the clinical development and supply of DWRX2003 for India"

About Daewoong Pharmaceutical: Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a South Korea based global healthcare group that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Daewoong has constructed various collaboration infrastructure including research, development, manufacturing, sales, etc. with clients & actively distributes products desired by local markets to strengthen its local competitiveness. Daewoong has eight branch offices in India, Asia and USA, five R&D centers and more than 100 partners worldwide.

About Mankind Pharma: Mankind is one of the top 5 leading pharmaceutical companies in India with a top line revenue approximating 1 billion USD. Mankind Pharma is a fully-integrated pharmaceutical company established in 1995 with a wide range of prescription and OTC products & a significant employee base of more than 14000. The global footprint of Mankind spreads across USA, Asia, Africa, Latin America & CIS Nations with presence in more than 30 countries. Mankind Research Centre (MRC), based at Manesar near Gurugram in Delhi/NCR, is a state of the art research facility with over 550 scientists involved in complex and innovative research. Since inception, Mankind Pharma’s mission statement has been to provide cost-effective, affordable & innovative superior quality pharmaceutical products across the globe to improve the lives of the patients.


FAQs answered by Dr. N. Krishna Reddy, Senior Cardiologist and Country Director of ACCESS Health India.


Do I have Covid-19?


Mumbai Aug 11th  If you have fever, head and body aches, cough, breathlessness, sore throat etc. (flu like symptoms) and if you think you have been likely exposed to a Covid-19 positive case (caring for a known case, visit to public place where social distancing was not followed, visit to a hospital or dialysis setting etc.), there is a possibility that you may have Covid-19.


What should I do if I have flu like symptoms?


It is preferable to get a medical consultation through telephone, smartphone, or online. You can reach out to your own doctor or to any online consultation provider or any helpline. Based on your symptoms and vitals (heart rate, blood pressure, breath rate, oxygen levels that are easily measured through home devices or wearable devices), you may be asked to get a few tests done. These may include blood cell counts and chest X-ray. Based on clinical assessment, your doctor may advise you to get tested for the Covid-19 virus. Sometimes he/ she may order a CT scan of the chest. It is advisable to self-isolate if you have flu like symptoms, until you get the virus test results.


What Covid-19 test should I undergo?


You should undergo a virus-detection test. There are two types of virus detection tests available – one, based on RT-PCR and the other based on Antigen detection. While RT-PCR may take one to two days to get the report, antigen detection report can be made available on the spot or in few hours. Your doctor should interpret the test results and inform you. A negative test may not completely rule out Covid-19, especially if your clinical assessment is strongly diagnostic of Covid. Similarly, a positive test is not always confirmatory, especially in the setting of low clinical suspicion. If your antigen test is negative, you should undergo RT-PCR test to be sure. However, if your antigen test is positive, you are indeed Covid positive. If your RT-PCR is negative, but clinical suspicion is high, you should repeat the test after 4 days. If your RT-PCR is positive, it means that you do have Covid. In rare cases, contamination at the lab may give false positive results with RT-PCR test.  


What should I do if I test positive?


Your doctor shall decide if you can be managed at home or if you need hospitalization. If you have mild symptoms without any breathing difficulty and your oxygen levels are above 93%, you can be managed at home. If you have home monitoring and oxygen services, you can be managed at home with close monitoring. You should also have facilities for proper isolation at home. If not, it is better to get admitted in a notified isolation facility. About 5 to 10% of cases may require hospitalization for ICU care. If you are elderly, and have other chronic conditions like diabetes, high blood pressure, heart, kidney and lung disease, it is better to get hospitalized until you start recovering. 


What precautions should I take when I am in home isolation?


You should have a separate room along with a separate bathroom, if possible. People who care for you should have personal protection in the form of face mask and hand sanitization. It is advised not to share utensils and clothing that you use during isolation. If you have vulnerable people (elderly and people with various comorbidities) at home, they should take extra precautions. You should avail of the various helplines available. Public health personnel may take appropriate containment steps as per guidelines. You should fully cooperate with them in order to prevent local spread in the community.   


Where should I go if I need hospitalization?


You should have a list of notified hospitals (government and private) that are treating Covid cases. If you have some form of health insurance or are eligible for government schemes, you should get all the information on what Covid treatment is covered and by which hospitals, from your insurer. You should also gather information on the availability of good quality intensive care services and vacant beds. It is also good to gather information on approximate costs in each hospital so that you can shortlist hospitals as per quality and affordability.


Should I stock any drugs?


You should not stock up on any drugs or self-medicate. You should be strictly managed as per published or emerging guidelines. While approved drugs based on strong scientific evidence are limited, there are few other treatments that are given as part of an ongoing study. If you are advised costly drugs, you should seek information on the quantum and type of extra benefit by use of these drugs. Unnecessary stocking of drugs or oxygen supplies creates shortages to those who really need these.


When do I need a ventilator?


Around 5% of positive cases may need ventilator. The need is higher in vulnerable people (elderly and those with other chronic illnesses). When you are unable to maintain adequate oxygen levels despite oxygen administration from outside and developing severe breathlessness, we take a decision to assist injured lungs with ventilator support.


How should I protect myself from getting the virus?


Appropriate face mask, hand sanitization, and social distancing (maintaining 6 feet distance, avoiding crowded public places or functions) reduces the risk of getting the infection to less than 5%. If you are a healthcare worker or if you are caring directly for an affected family member, you should wear the disposable surgical mask. If you are involved in direct care of patient requiring aerosol generating procedures like nebulization, non-invasive ventilation, care of ventilated patient, it is advisable to wear N95 mask. In all other situations a reusable, appropriately designed cloth mask should suffice. You can re-sterilize N95 masks by keeping them in UV light chambers for 15 minutes or Hydrogen Peroxide vapors, if available.


How should I protect others if I am infected?


Self-isolation or facility-based isolation is the best method to prevent the spread. Providing information on people who might have come in contact with you a day or two before you developed the symptoms or after the onset of symptoms is vital to test and quarantine them.


How do I know if I am infected without developing illness?


Majority of people either remain asymptomatic or develop very mild symptoms that are ignored. If you think you might have been exposed to the virus, you can get an antibody-based serological test. Body develops antibodies in response to the virus infection as part of its defense mechanism. There are two types of antibodies – IgM and IgG. IgM antibodies appear within 1 week of infection, while IgG antibodies appear in two weeks. A positive serology test indicates that you have been already infected with Covid virus. While presence of IgM indicates a recent infection, presence of IgG indicates that you might have been infected prior to two weeks. While IgM antibodies disappear soon, IgG antibodies persist for long period of time. These antibodies are supposed to offer protection against reinfection. However, we still do not know as to which antibodies offer protection and for how long. A test that detects protective IgG (neutralizing) antibodies might suggest that you are protected against reinfection for at least 90 days. However, scientific evidence is yet to come to give such an assurance.  


What should I do if I need medical attention for other health problems?


It is very important to not neglect other medical problems during the Covid pandemic. Children should get their vaccines. Pregnant women should get recommended antenatal checks. Ongoing treatment for chronic diseases like tuberculosis, HIV, diabetes, hypertension, heart, lung, kidney diseases should be continued without fail. Wherever possible, it is better to get services direct to home in order to avoid visiting clinics, hospitals, pharmacies and diagnostic centers where the probability of contracting an infection inadvertently may be higher. However, symptoms suggestive of acute heart pain or brain stroke should not be neglected and you should not hesitate to go to emergencies. You should have a list of non-Covid hospitals to manage these. Some of the notified Covid hospitals also attend to other medical problems. 


When can one  interact with someone who has recovered from COVID -19 and their family members?


Two weeks after the onset of symptoms is considered safe to interact. However, personal protection and social distancing should be continued as the virus may still be detected in few cases up to 4 weeks.


Is it safe to visit people in their homes or offices while taking precautions?


As long as people follow appropriate precautions, both at family gatherings and in offices, the risk of transmission is very minimal. Aerosols may linger in the air for longer period in closed, airconditioned offices or homes. N95 masks may be preferred if someone has to stay for longer periods in such spaces.


Can we use lifts with other people, what are the precautions one should take in closed spaces?


If people have adequate masks and follow hand sanitization after exiting a lift, there is no increased risk to share lifts.


What number is a mass gathering and why should we avoid them?


More than the number of people, it is the behaviour of the people that determines the risk of transmission.


Any other thing that I should know?


There is flood of misinformation on Covid-19 that you have to be cautious about. You can seek information on authoritative sites like WHO, CDC (USA), NICE (UK), Johns Hopkins School of Public Health, Imperial College, London and ICMR. Secondly, it is natural to get emotionally affected in these times. It is always useful to talk out these problems so that they do not lead to other problems. There are helplines to assist with emotional problems. Refrain from using untested drugs and cures.